Erlotinib Completed Phase 2 Trials for Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00369512A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
NCT00585377Bevacizumab (AvastinĀ®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer